Because Expertise Matters
Join Cyberounds®, an online education community for health professionals Sign Up

Log In

Nephrology

Erythropoietin in Progressive Renal Disease

This month, Eli A. Friedman, M.D. discusses
CME credit is no longer available for this conference.

Course Authors

Eli A. Friedman, M.D.

Release Date: 09/20/2001

 
Learning Objectives

Upon completion of this Cyberounds®, you should be able to:

  • Describe a broadly applicable new therapeutic option in renal therapy

  • Discuss the established actions of erythropoietin in end stage renal disease

  • Examine evidence -- thus far incomplete -- that erythropoietin treatment to correct anemia in patients who have substantive renal reserve - may be beneficial.

 

TERMS AND CONDITIONS

This conference may include discussion of commercial products and services.

The opinions expressed herein are those of the authors and do not necessarily represent the views of the sponsor or its publisher. Please review complete prescribing information of specific drugs or combination of drugs, including indications, contraindications, warnings and adverse effects before administering pharmacologic therapy to patients.

 

Please click below to accept the terms.

Courses You Might Like

Heat Stress, Climate Change, and Its Impact on Kidney Disease

The kidneys have a major role in maintaining a healthy extracellular environment within our bodies. They also try to protect us from alterations in temperature, humidity and when access to water or food is limited. to water or food is limited.
Authors: Fumihiko Sasai, M.D., Ashio Yoshimura, M.D. and Richard J Johnson, M.D.
View Course
More

Home Dialysis -- The Future Is Now

Patients may benefit both in terms of quality of life and improved dialysis metrics by performing home hemodialysis.
Authors: Annie-Claire Nadeau-Fredette, M.D., and Joanne M. Bargman, M.D.; Eduardo Alas, M.D., and Mark Unruh, M.D., M.S.
View Course
More

Diagnosis and Treatment of Kidney Cancer

Kidney cancer, unlike other genitourinary cancers, is increasing in incidence and this is not simply due to better diagnosis.
Authors: Robert H. Weiss, M.D. and Hiromi Inoue, D.V.M.
View Course
More

Nephrogenic Systemic Fibrosis

This month, Frieda Wolf, M.D., discusses

idiopathic disorder in patients with renal failure who develop fibrosis in skin and internal organs after exposure to gadolinium−containing contrast agents. NSF was first noted in 1997, and published in 2000 by Cowper in the Lancet. Fifteen cases of NSF were seen in 14 dialysis patients and one patient with…
Authors: Frieda Wolf, M.D.
View Course
More

Nephrotic Syndrome

The prognosis and therapy for nephrotic syndrome types differ.
Authors: Frieda Wolf, M.D.
View Course
More

Renal Transplantation: Immunity and Viral Infections

This month, Frieda Wolf, M.D., discusses

cascade of T cell activation. MHC class II proteins activate T helper cells by binding CD4 proteins on their surface. These helper cells further activate proliferation of subtypes of T cells some of which are other T helper cells, but others are cytotoxic T cells or memory T cells. …
Authors: Frieda Wolf, M.D.
View Course
More